Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Simon Property Group Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Simon Property Group Inc trades at $200.17 (market cap $64.92B). The key difference: Simon Property Group Inc is far larger — about 66.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Simon Property Group Inc pays a 4.44% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Simon Property Group Inc for 100 Days on average.
| MRVI | SPG | |
|---|---|---|
Market Cap | $972.90M | $64.92B |
Volume | 4,325,710 | 1,919,136 |
Sector | Health | Real Estate |
52-Week High | $9.00 | $236.70 |
52-Week Low | $2.83 | $173.35 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $1.08B | $93.37B |
Dividend Yield | — | 4.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SPG trades at $198.70, down 1.35% with bearish technical signals from moving averages and ADX indicators. The REIT maintains strong fundamentals with Q4 2025 EPS beating expectations at $9.35 versus $1.90, though Q2 2026 missed at $1.49 versus $1.64. Recent news highlights strong leasing demand and a new $800 million debt issuance, while directors made small stock purchases in late September 2026.
SPG presents a mixed outlook with robust profitability metrics like 66.57% net margin and 135.7% ROE offset by negative net cash flow and high debt levels. The consensus price target of $218.45 suggests 10% upside potential, but rising bond yields and $2B in 2024 debt maturities pose headwinds for the retail REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
